The Science
The misnamed hormone: what α-MSH actually is
In this piece
The hormone at the centre of this whole story is misnamed, and the name is worth taking apart, because almost everything the gray market gets wrong about it follows from believing the label.
“Melanocyte-stimulating hormone” was christened for a party trick. In the 1950s, when Aaron Lerner and his colleagues isolated the peptide from pituitary glands, the way you measured it was to drop it onto a piece of frog or lizard skin and watch the skin darken — pigment granules fanning out across the melanophores within minutes. It was a dramatic, visible, quantifiable response, and it gave the molecule its name. The name records what pituitary extract did to a cold-blooded animal on a lab bench. It does not describe what the peptide is to you.
What it actually is
α-MSH is a short peptide — thirteen amino acids, written Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂, with a chemically capped head and tail. Buried in the middle is the four-residue stretch His-Phe-Arg-Trp, the “message sequence”: the minimal core that the receptor actually reads. Everything the Arizona chemists did a generation later was an attempt to amplify and stabilise that message. It is the pharmacophore every Melanotan was cut to fit.
The body does not keep α-MSH in a gland and release it into the bloodstream like a classic hormone. It makes it on the spot. α-MSH is one of several fragments cut from a much larger precursor protein, pro-opiomelanocortin, or POMC — the same precursor that yields ACTH and β-endorphin. Different tissues cut POMC differently, so the same parent protein becomes a stress hormone in one place and a pigment signal in another.
Where it comes from, and when
In skin, the trigger is damage. Ultraviolet light breaks DNA in keratinocytes — the structural cells of the epidermis — and that damage stabilises the p53 protein, the cell’s emergency switch. p53 binds the POMC gene and turns it on. The keratinocyte cuts α-MSH from the POMC it has just made and releases it to the pigment cells sitting next to it. Those melanocytes carry MC1R on their surface; α-MSH binds it, cAMP rises inside the cell, the master pigment regulator MITF is switched up, and the cell starts manufacturing eumelanin — the brown-black pigment that absorbs UV. That is a tan: a wound response, pigment made only after the harm that called for it.
The two things the name hides
Read that pathway again and two features stand out, neither of them in the word “hormone.”
The first is that α-MSH is local. It is released microns from where it acts, into the gap between a keratinocyte and the pigment cell beside it. It is not a courier dispatched through the bloodstream to the whole body.
The second is that it is brief. Plasma enzymes degrade α-MSH within minutes. The signal is designed to be weak and fleeting — switched on by damage, read by the cell next door, and erased almost immediately.
Those are not shortcomings. They are the control system. The body tunes pigment with a signal it can start and stop fast, in one small patch of skin, because unbounded pigment-making everywhere, all the time, is not something a body wants. The feebleness is the feature.
If you came here looking for an agonist
An agonist is a key that turns a receptor on. For the colour and limited UV defence the original researchers wanted, the address is MC1R on a melanocyte. α-MSH is the body’s key. Melanotan II is a synthetic, longer- lasting key that also turns other melanocortin locks. It is not the body’s own α-MSH, and it is not a supply of melanin. It changes a signal; the melanocyte still has to make, package and transfer the pigment.
That distinction separates three outcomes the phrase “protective tan” collapses:
- Agonism: the receptor was switched on.
- Pigmentation: skin became darker because cells made melanin.
- Protection: a meaningful reduction in UV injury or skin cancer was measured in people.
The first two do not establish the third. Eumelanin absorbs and scatters UV, but pigment is not a force field. Australia’s medicines regulator says explicitly that melanotan-induced pigmentation will not protect against UV exposure the way a suitable sunscreen will, and no trial has shown that Melanotan II prevents skin cancer. A darker appearance therefore cannot be used as permission for more sun or less protection.
The beauty part is not programmable either. A systemic signal reaches pigment cells indiscriminately; it does not read cheekbones, symmetry, a photograph or a preferred shade. The same biology can mean a tan, conspicuous freckles, changing moles and dark nail bands. The desired colour and the unwanted pigment are both the receptor being activated.
So the useful question is not “how do I get more agonist?” It is “can a drug activate the right receptor, in the right tissue, with a measured benefit and an acceptable safety record?” For Melanotan II, those answers have not been established. For the research goal, see what a safe tanning drug would actually have to be.
Why this is the whole story
Hold that picture next to what the gray market injects, and the gap is the entire point. The lab did not discover a new signal; it took the body’s deliberately-feeble one and rebuilt it to be relentless. The two amino-acid swaps that made Melanotan’s superpotent ancestor — norleucine for the oxidation-prone methionine, a D-form phenylalanine the enzymes can’t cut — exist precisely to defeat the “cleared in minutes” design. Cyclisation and injection defeat the “made where it’s needed” design. What is left is the same message sequence, reading the same receptor, but now circulating for hours and reaching every melanocortin receptor in the body — the appetite ones, the arousal ones, the ones in the brain.
The three levers in that rebuild — potency, super-potency, and duration — are separated in potent, super-potent, relentless. That is why a single peptide tans, sickens, and arouses at once. It is not a mysterious property of the molecule. It is what happens when you take a whisper the body meant to last a moment in one spot and turn it into a shout that lasts all day everywhere. When the market says Melanotan is “just a hormone your body makes,” the honest translation is: it is patterned on one, and engineered against every safeguard that made the original safe to have.
And pigment, finally, is only one of α-MSH’s jobs. The same peptide family is woven into inflammation, energy balance, and more — which is another way of saying the body never built this signal to be a tanning switch you could leave on. The human evidence for that — skin that darkens when the signal is stuck high, and stays pale when it is missing — is too much, too little. The body built a brief, local message and gave it a name, seventy years ago, for the one thing it did to a frog.
Common questions
What is α-MSH?
α-MSH (alpha-melanocyte-stimulating hormone) is a small 13-amino-acid peptide the body cuts from a larger precursor protein called POMC. In skin it is released locally — mostly by UV-damaged keratinocytes — and tells neighbouring pigment cells to make the brown pigment that darkens a tan. It is also cleared within minutes, so its signal is brief by design.
Is α-MSH the same thing as Melanotan?
No. Melanotan I and II are engineered analogs patterned on α-MSH, not the hormone itself. The lab versions were deliberately altered to resist the enzymes that destroy natural α-MSH and to act far longer and more broadly — which is exactly why an injected analog produces whole-body effects the local hormone never would.
Does the body make α-MSH when you tan?
Yes. Ultraviolet light damages skin-cell DNA, which stabilises the p53 protein; p53 switches on the POMC gene, and the α-MSH cut from POMC drives the pigment response. The natural tan is a damage signal — the pigment arrives only after the harm that triggered it.